From: A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
Level | Imatinib | Dacarbazine | Capecitabine | Patients (N) | Dose reductions (N) | DLTs1(N and type) |
---|---|---|---|---|---|---|
−1 | 300 mg | 250 mg/m2 | 500 mg/m2 BID | 6 | 0 | 1 (fatigue) |
1 | 400 mg | 250 mg/m2 | 500 mg/m2 BID | 6 | 2 | 9 (Dyspnea, Fatigue, Diarrhea, Dehydration, Nausea, Ocular Surface Disease, Insomnia) |
2 | 400 mg | 330 mg/m2 | 750 mg/m2 BID | 6 | 1 | 2 (Hypokalemia, platelets) |
3 | 400 mg | 330 mg/m2 | 1000 mg/m2 BID | 0 | 0 | |
4 | 600 mg | 330 mg/m2 | 1000 mg/m2 BID | 0 | 0 | |
5 | 800 mg | 330 mg/m2 | 1000 mg/m2 BID | 0 | 0 |